{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:01:09Z","timestamp":1780657269374,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T00:00:00Z","timestamp":1547510400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2018SK2124"],"award-info":[{"award-number":["2018SK2124"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12967-018-1734-x","type":"journal-article","created":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T08:02:52Z","timestamp":1547539372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients"],"prefix":"10.1186","volume":"17","author":[{"given":"Jingyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yikai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongzhi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quchang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,15]]},"reference":[{"key":"1734_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","volume":"25","author":"LA Torre","year":"2016","unstructured":"Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends\u2014an update. Cancer Epidemiol Biomarkers Prev. 2016;25:16\u201327.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1734_CR2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4048\/jbc.2015.18.2.160","volume":"18","author":"S Park","year":"2015","unstructured":"Park S, Han W, Kim J, Kim MK, Lee E, Yoo TK, Lee HB, Kang YJ, Kim YG, Moon HG, Noh DY. Risk factors associated with distant metastasis and survival outcomes in breast cancer patients with locoregional recurrence. J Breast Cancer. 2015;18:160\u20136.","journal-title":"J Breast Cancer"},{"key":"1734_CR3","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","volume":"29","author":"F Cardoso","year":"2018","unstructured":"Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, Andre F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)dagger. Ann Oncol. 2018;29:1634\u201357.","journal-title":"Ann Oncol"},{"key":"1734_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1677\/erc.0.0070017","volume":"7","author":"AE Wakeling","year":"2000","unstructured":"Wakeling AE. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer. 2000;7:17\u201328.","journal-title":"Endocr Relat Cancer"},{"key":"1734_CR5","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1200\/JCO.2002.10.057","volume":"20","author":"A Howell","year":"2002","unstructured":"Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20:3396\u2013403.","journal-title":"J Clin Oncol"},{"key":"1734_CR6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10549-010-1022-9","volume":"123","author":"KI Pritchard","year":"2010","unstructured":"Pritchard KI, Rolski J, Papai Z, Mauriac L, Cardoso F, Chang J, Panasci L, Ianuli C, Kahan Z, Fukase K, et al. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Res Treat. 2010;123:453\u201361.","journal-title":"Breast Cancer Res Treat"},{"key":"1734_CR7","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1093\/annonc\/mdq249","volume":"21","author":"S Ohno","year":"2010","unstructured":"Ohno S, Rai Y, Iwata H, Yamamoto N, Yoshida M, Iwase H, Masuda N, Nakamura S, Taniguchi H, Kamigaki S, Noguchi S. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). Ann Oncol. 2010;21:2342\u20137.","journal-title":"Ann Oncol"},{"key":"1734_CR8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10549-011-1947-7","volume":"133","author":"I Kuter","year":"2012","unstructured":"Kuter I, Gee JM, Hegg R, Singer CF, Badwe RA, Lowe ES, Emeribe UA, Anderson E, Sapunar F, Finlay P, et al. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study. Breast Cancer Res Treat. 2012;133:237\u201346.","journal-title":"Breast Cancer Res Treat"},{"key":"1734_CR9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/cncr.21163","volume":"104","author":"A Howell","year":"2005","unstructured":"Howell A, Pippen J, Elledge RM, Mauriac L, Vergote I, Jones SE, Come SE, Osborne CK, Robertson JF. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer. 2005;104:236\u20139.","journal-title":"Cancer"},{"key":"1734_CR10","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1200\/JCO.2010.28.8415","volume":"28","author":"A Leo Di","year":"2010","unstructured":"Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250\u00a0mg with fulvestrant 500\u00a0mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28:4594\u2013600.","journal-title":"J Clin Oncol"},{"key":"1734_CR11","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","volume":"388","author":"JFR Robertson","year":"2016","unstructured":"Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, et al. Fulvestrant 500\u00a0mg versus anastrozole 1\u00a0mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388:2997\u20133005.","journal-title":"Lancet"},{"key":"1734_CR12","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s10549-017-4212-x","volume":"163","author":"H Kawaguchi","year":"2017","unstructured":"Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Tokunaga E, et al. Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari). Breast Cancer Res Treat. 2017;163:545\u201354.","journal-title":"Breast Cancer Res Treat"},{"key":"1734_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2016.02.004","volume":"45","author":"J Graham","year":"2016","unstructured":"Graham J, Pitz M, Gordon V, Grenier D, Amir E, Niraula S. Clinical predictors of benefit from fulvestrant in advanced breast cancer: a meta-analysis of randomized controlled trials. Cancer Treat Rev. 2016;45:1\u20136.","journal-title":"Cancer Treat Rev"},{"key":"1734_CR14","first-page":"1579","volume":"38","author":"Y Koi","year":"2018","unstructured":"Koi Y, Koga C, Akiyoshi S, Masuda T, Ijichi H, Nakamura Y, Ishida M, Ohno S, Tokunaga E. Impact of visceral metastasis on efficacy of fulvestrant in patients with hormone receptor-positive recurrent breast cancer. Anticancer Res. 2018;38:1579\u201384.","journal-title":"Anticancer Res"},{"key":"1734_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jsbmb.2016.11.017","volume":"167","author":"K Tsuboi","year":"2017","unstructured":"Tsuboi K, Kaneko Y, Nagatomo T, Fujii R, Hanamura T, Gohno T, Yamaguchi Y, Niwa T, Hayashi SI. Different epigenetic mechanisms of ERalpha implicated in the fate of fulvestrant-resistant breast cancer. J Steroid Biochem Mol Biol. 2017;167:115\u201325.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1734_CR16","doi-asserted-by":"publisher","first-page":"18060","DOI":"10.1073\/pnas.1018858109","volume":"109","author":"ST Bailey","year":"2012","unstructured":"Bailey ST, Shin H, Westerling T, Liu XS, Brown M. Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proc Natl Acad Sci USA. 2012;109:18060\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1734_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13058-018-0983-1","volume":"20","author":"R Ribas","year":"2018","unstructured":"Ribas R, Pancholi S, Rani A, Schuster E, Guest SK, Nikitorowicz-Buniak J, Simigdala N, Thornhill A, Avogadri-Connors F, Cutler RE Jr, et al. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer. Breast Cancer Res. 2018;20:44.","journal-title":"Breast Cancer Res"},{"key":"1734_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11912-017-0591-8","volume":"19","author":"R Jeselsohn","year":"2017","unstructured":"Jeselsohn R, De Angelis C, Brown M, Schiff R. The evolving role of the estrogen receptor mutations in endocrine therapy-resistant breast cancer. Curr Oncol Rep. 2017;19:35.","journal-title":"Curr Oncol Rep"},{"key":"1734_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41523-018-0075-5","volume":"4","author":"Y Kuang","year":"2018","unstructured":"Kuang Y, Siddiqui B, Hu J, Pun M, Cornwell M, Buchwalter G, Hughes ME, Wagle N, Kirschmeier P, Janne PA, et al. Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer. NPJ Breast Cancer. 2018;4:22.","journal-title":"NPJ Breast Cancer"},{"key":"1734_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ebiom.2018.05.015","volume":"32","author":"ZY Hu","year":"2018","unstructured":"Hu ZY, Xie N, Tian C, Yang X, Liu L, Li J, Xiao H, Wu H, Lu J, Gao J, et al. Identifying circulating tumor DNA mutation profiles in metastatic breast cancer patients with multiline resistance. EBioMedicine. 2018;32:111\u20138.","journal-title":"EBioMedicine"},{"key":"1734_CR21","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10549-010-0747-9","volume":"120","author":"RE Board","year":"2010","unstructured":"Board RE, Wardley AM, Dixon JM, Armstrong AC, Howell S, Renshaw L, Donald E, Greystoke A, Ranson M, Hughes A, Dive C. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat. 2010;120:461\u20137.","journal-title":"Breast Cancer Res Treat"},{"key":"1734_CR22","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1002\/ijc.29265","volume":"136","author":"J Madic","year":"2015","unstructured":"Madic J, Kiialainen A, Bidard FC, Birzele F, Ramey G, Leroy Q, Rio Frio T, Vaucher I, Raynal V, Bernard V, et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int J Cancer. 2015;136:2158\u201365.","journal-title":"Int J Cancer"},{"key":"1734_CR23","doi-asserted-by":"publisher","DOI":"10.1067\/j.cpradiol.2018.07.016","author":"UR Lalchandani","year":"2018","unstructured":"Lalchandani UR, Sahai V, Hersberger K, Francis IR, Wasnik AP. A radiologist\u2019s guide to response evaluation criteria in solid tumors. Curr Probl Diagn Radiol. 2018. \n                    https:\/\/doi.org\/10.1067\/j.cpradiol.2018.07.016\n                    \n                  .","journal-title":"Curr Probl Diagn Radiol"},{"key":"1734_CR24","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/annonc\/mdn670","volume":"20","author":"ED Saad","year":"2009","unstructured":"Saad ED, Katz A. Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined. Ann Oncol. 2009;20:460\u20134.","journal-title":"Ann Oncol"},{"key":"1734_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.clbc.2017.07.015","volume":"18","author":"L Li","year":"2018","unstructured":"Li L, Pan Z. Progression-free survival and time to progression as real surrogate end points for overall survival in advanced breast cancer: a meta-analysis of 37 trials. Clin Breast Cancer. 2018;18:63\u201370.","journal-title":"Clin Breast Cancer"},{"key":"1734_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s13402-018-0376-6","volume":"41","author":"M Yousefi","year":"2018","unstructured":"Yousefi M, Nosrati R, Salmaninejad A, Dehghani S, Shahryari A, Saberi A. Organ-specific metastasis of breast cancer: molecular and cellular mechanisms underlying lung metastasis. Cell Oncol (Dordr). 2018;41:123\u201340.","journal-title":"Cell Oncol (Dordr)"},{"key":"1734_CR27","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ccr.2011.11.002","volume":"20","author":"X Lu","year":"2011","unstructured":"Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, Yan J, Hua Y, Tiede BJ, Haffty BG, et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell. 2011;20:701\u201314.","journal-title":"Cancer Cell"},{"key":"1734_CR28","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","volume":"12","author":"R Jeselsohn","year":"2015","unstructured":"Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015;12:573\u201383.","journal-title":"Nat Rev Clin Oncol"},{"key":"1734_CR29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12967-017-1204-x","volume":"15","author":"J Sun","year":"2017","unstructured":"Sun J, Huang Z, Hu Z, Sun R. Benefits of local tumor excision and pharyngectomy on the survival of nasopharyngeal carcinoma patients: a retrospective observational study based on SEER database. J Transl Med. 2017;15:116.","journal-title":"J Transl Med"},{"key":"1734_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12967-017-1239-z","volume":"15","author":"A Bettaieb","year":"2017","unstructured":"Bettaieb A, Paul C, Plenchette S, Shan J, Chouchane L, Ghiringhelli F. Precision medicine in breast cancer: reality or utopia? J Transl Med. 2017;15:139.","journal-title":"J Transl Med"},{"key":"1734_CR31","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425\u201339.","journal-title":"Lancet Oncol"},{"key":"1734_CR32","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1200\/JCO.2017.76.9331","volume":"36","author":"N Kornblum","year":"2018","unstructured":"Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A, Stella PJ, Burnette B, Telli M, Makower DF, et al. Randomized phase II trial of Fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102. J Clin Oncol. 2018;36:1556\u201363.","journal-title":"J Clin Oncol"},{"key":"1734_CR33","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martin M, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465\u201372.","journal-title":"J Clin Oncol"},{"key":"1734_CR34","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12967-018-1495-6","volume":"16","author":"P Kundig","year":"2018","unstructured":"Kundig P, Giesen C, Jackson H, Bodenmiller B, Papassotirolopus B, Freiberger SN, Aquino C, Opitz L, Varga Z. Limited utility of tissue micro-arrays in detecting intra-tumoral heterogeneity in stem cell characteristics and tumor progression markers in breast cancer. J Transl Med. 2018;16:118.","journal-title":"J Transl Med"},{"key":"1734_CR35","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/1479-5876-11-190","volume":"11","author":"X Wang","year":"2013","unstructured":"Wang X, Yang Q, Guo L, Li XH, Zhao XH, Song LB, Lin HX. Flotillin-2 is associated with breast cancer progression and poor survival outcomes. J Transl Med. 2013;11:190.","journal-title":"J Transl Med"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-018-1734-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-018-1734-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-018-1734-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T09:18:41Z","timestamp":1580721521000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-018-1734-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,15]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1734"],"URL":"https:\/\/doi.org\/10.1186\/s12967-018-1734-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,15]]},"assertion":[{"value":"17 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"27"}}